October 30, 2001

Endocardial Solutions Installs 200th System

MINNEAPOLIS / ST.PAUL -- Endocardial Solutions, Inc. (Nasdaq: ECSI) today announced the 200th installation of its EnSite 3000® System for mapping cardiac arrhythmias at Northeast Baptist Hospital in San Antonio, Texas.

“The best measure of acceptance for any new technology is success in the marketplace. The placement of our 200th system is a key milestone in ESI’s effort to establish the EnSite 3000® System as the standard of care for electrophysiologists, payers, and patients in search of better tools for the management of arrhythmias,” stated Mike Dale, VP of Sales and Marketing.

<*dv_2*>Northeast Baptist Hospital is a major provider of cardiac care in San Antonio and is part of the Baptist Health System, a leading provider of cardiac and emergency care in San Antonio and South Texas. “We’re excited to introduce the EnSite 3000® System to San Antonio,” said Dr. Gregory Buser, Medical Director of EP and Cath labs at Northeast Baptist Hospital. “The system’s ability to map an entire heart chamber in a single beat will allow us to treat previously untreatable patients.”

<*dv_1*>About Endocardial Solutions
Based in St. Paul, Minnesota, Endocardial Solutions (www.endocardial.com) develops, manufactures and markets technology for diagnostic mapping of complex arrhythmias (abnormally rapid heartbeats caused by irregular electrical activity in the heart). The EnSite 3000® System provides a 3D graphical display of the heart’s electrical activity. The U.S. Food and Drug Administration cleared the EnSite 3000® System for use in diagnostic mapping of complex arrhythmias in the right atrium of the heart during the second quarter 1999.

<*dv_0*> The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. A number of factors should be considered in conjunction with these forward-looking statements. These factors are set forth in the cautionary statements included in Exhibit 99 to Endocardial Solutions’ Form 10-K/A for the year ended December 31, 2000, filed with the Securities and Exchange Commission. Endocardial Solutions cautions investors and others to review the statements set forth in that report and that other factors may prove to be important in affecting the business and results of operations of Endocardial Solutions.

Contacts:
Jim Bullock, President and CEO, Endocardial Solutions (651) 523-6928 jbullock@endocardial.com

<*dv_3*>Brenda Gutzke, Investor Relations, Endocardial Solutions (651) 523-6959 bgutzke@endocardial.com